Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839626 | 0.85 | GPR132 (0.47) | CTSLCTSBCTSSALDH1A1CTSK | |
| SCHEMBL1838049 | 0.81 | GPR132 (0.46) | CTSLCTSBCTSSALDH1A1CTSK | |
| SCHEMBL1840374 | 0.79 | GPR132 (0.52) | MAPTALDH1A1GPR132HDAC1HDAC6 | |
| SCHEMBL1841568 | 0.78 | CNR2 (0.52) | MAPTALDH1A1CNR2 | |
| SCHEMBL1839537 | 0.78 | GAA (0.46) | MAPTCTSLCTSBCTSSALDH1A1 | |
| SCHEMBL11928967 | 0.77 | CTSL (0.48) | MAPTCTSLCTSBCTSSCTSK | |
| SCHEMBL1812184 | 0.76 | HDAC3 (0.40) | MAPTDGAT2CTSLCTSBCTSS | |
| SCHEMBL1811633 | 0.75 | PDE4D (0.47) | DGAT2HDAC1LPAR1CNR2 | |
| SCHEMBL1811403 | 0.75 | DGAT2 (0.47) | MAPTDGAT2CTSLCTSBCTSS | |
| SCHEMBL1977381 | 0.75 | PLK1 (0.54) | MAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785631-B2 | Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core | SEIKAGAKU CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| CN-101370773-B | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD | 2014-04-09 | — | — | CN | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131661-A1 | Oxazolone Derivatives | SEIKAGAKU CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2036920-A1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1975162-A1 | OXAZOLONE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1972636-A1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131661-A1 | Oxazolone Derivatives | CTSK, CTSZ, CTSV | MAPT 4572/4885DGAT2 4308/4885CTSL 7/4885 |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | CTSK, CTSS, CTSV | MAPT 3842/4885DGAT2 4071/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.